ArticleHistochemistry and cell biology2010
Histomorphometric evaluation of cannabinoid receptor and anandamide modulating enzyme expression in the human endometrium through the menstrual cycle.
Article in Histochemistry and cell biology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 77 citations in OpenAlex.
- Fatty Acid Amide Hydrolase Signaling and Ovarian Disorders: From Molecular Mechanism to Clinical Significance.Molecules (Basel, Switzerland) · 2026Review
- Placental Cannabinoid Receptor Expression in Preterm Birth.Journal of pregnancy · 2024Observational
- Labour and premature delivery differentially affect the expression of the endocannabinoid system in the human placenta.Histochemistry and cell biology · 2023Article
- Role of CB1 Cannabinoid Receptors in Vascular Responses and Vascular Remodeling of the Aorta in Female Mice.International journal of molecular sciences · 2023Article
- Review
- Serine Hydrolases in Lipid Homeostasis of the Placenta-Targets for Placental Function?International journal of molecular sciences · 2022Review
- Gene expression of the endocannabinoid system in endometrium through menstrual cycle.Scientific reports · 2022Article
- Article
- (Endo)Cannabinoids and Gynaecological Cancers.Cancers · 2020Review
- The fundamental role of the endocannabinoid system in endometrium and placenta: implications in pathophysiological aspects of uterine and pregnancy disorders.Human reproduction update · 2020Review
- Cannabinoids in Gynecological Diseases.Medical cannabis and cannabinoids · 2019Review
- Mice Missing Cnr1 and Cnr2 Show Implantation Defects.Endocrinology · 2019Article
- New Insights of Uterine Leiomyoma Pathogenesis: Endocannabinoid System.Medical science monitor basic research · 2019Article
- Expression and Function of the Endocannabinoid Modulating Enzymes Fatty Acid Amide Hydrolase andFrontiers in oncology · 2019Article
- Identification of Novel Predictive Biomarkers for Endometrial Malignancies:Frontiers in oncology · 2019Article
- Decreased Expression of Cannabinoid Receptors in the Eutopic and Ectopic Endometrium of Patients with Adenomyosis.BioMed research international · 2019Article
- Marijuana use differentially affects cannabinoid receptor expression in early gestational human endometrium and placenta.Placenta · 2018Article
- Cannabinoid-induced cell death in endometrial cancer cells: involvement of TRPV1 receptors in apoptosis.Journal of physiology and biochemistry · 2018Article
- A Metabolomic Overview of Follicular Fluid in Cows.Frontiers in veterinary science · 2018Article
- The CBCellular and molecular life sciences : CMLS · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plasma anandamide (AEA) levels fluctuate throughout the menstrual cycle and in early pregnancy in a pattern suggesting its involvement in implantation and early pregnancy maintenance through mechanisms that might involve its binding to cannabinoid receptors CB1 and CB2. Plasma AEA levels are maintained by the actions of the enzymes fatty acid amide hydrolase (FAAH) and N-acylphosphatidylethanolamine-phospholipase D (NAPE-PLD). All of these component parts of the 'endocannabinoid system' have been demonstrated in rodent but not in human uteri. This study aimed to demonstrate the presence of the endocannabinoid system in the human uterus and catalogue its modulation. Immunohistochemical techniques were employed to localise and determine the distribution of immunoreactive CB1, CB2, FAAH, and NAPE-PLD in well-characterised menstrual cycle biopsy samples. Immunoreactive CB1 and CB2 were widely distributed throughout the uterine tissue. In the myometrium and endometrium, smooth muscle cells were immunoreactive, although the vascular smooth muscle cells in both tissues were more so. In the endometrium, CB1 and CB2 immunoreactivity was primarily restricted to the glandular epithelium and expression was unrelated to the phase of the cycle. FAAH immunoreactivity in the endometrium was highest in the mid-proliferative gland and mid-secretory stroma, whilst NAPE-PLD immunoreactivity was down-regulated in the secretory epithelial gland compared to the proliferative epithelial gland and unaffected in the stroma. These data indicate that elements of the 'endocannabinoid system' coexist in many cell types within the uterus and may provide insight into the sites of action of endogenous and exogenous cannabinoids during endometrial transformation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.